The National Institute for Health and Care Excellence has recommended an integrated automated glucose monitoring system for patients with type 1 diabetes.
NICE has today published final diagnostics guidance backing the MiniMed Paradigm Veo System (Medtronic) for managing blood glucose levels.
“Using the system may also make it easier for people to stick to their treatment”
The guidance recommends the system as an option for type 1 diabetes patients who experience frequent episodes of hypoglycaemia, despite optimal management with insulin pump therapy.
NICE estimated that around 30% of people with type 1diabetes have problematic hypoglycaemia.
The MiniMed Paradigm Veo system consists of a glucose sensor placed under the skin that continuously measures glucose levels, an insulin pump and a transmitter that sends glucose level readings wirelessly from the sensor to the pump.
The system alerts the user if glucose levels become too high or low, if levels are rapidly changing, or if the system predicts levels will be too high or too low in the near future.
An automated low glucose suspend function operates independently of user action and stops insulin delivery for two hours if the user fails to respond to the alert.
Glucose monitoring system backed for type 1 diabetes
Professor Carole Longson, director of the NICE Health Technology Evaluation Centre, said: “The [independent diagnostics advisory] committee concluded that using the MiniMed Paradigm Veo System may help people with type 1 diabetes improve their glucose control. Using the system may also make it easier for people to stick to their treatment.
“The ability of the system to automatically suspend insulin delivery when it detects that a person’s glucose levels have become too low could help in reducing the incidence of hypoglycaemia that happens during sleep and the associated anxiety,” she added.
“The system could also offer benefits to the NHS through cost and resource savings by reducing the number of hospital admissions and consultations associated with diabetes-related complications,” said Professor Longson.
A further integrated automated glucose monitoring system without a low glucose suspend function – the Vibe and G4 PLATINUM CGM system – was also considered as part of this evaluation.
The NICE committee concluded that the system showed promise but there was currently not enough evidence to support its routine adoption in the NHS and more evidence was “needed to demonstrate its clinical effectiveness in practice”.